CD52 and graft versus host disease: Multiplexed knockouts prevented expression of αβ T-cell receptor (TCRαβ) to avoid graft-versus-host disease (GvHD), disrupted CD7 to evade self-targeting through the anti-CD7 CAR, and removed CD52 to confer resistance to the lymphodepleting antibody Alemtuzumab [13].